Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
03 10 2019
Historique:
received: 02 03 2019
accepted: 26 06 2019
pubmed: 12 7 2019
medline: 1 2 2020
entrez: 12 7 2019
Statut: ppublish

Résumé

T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of novel treatment options that will potentially change the management of patients with T-PLL, it has become necessary to produce consensus guidelines for the design and conduct of clinical trials. The T-PLL International Study group (TPLL-ISG) set out to define standardized criteria for diagnosis, treatment indication, and evaluation of response. These criteria will facilitate comparison of results from clinical trials in T-PLL, and will thus support clinical decision making, as well as the approval of new therapeutics by healthcare authorities.

Identifiants

pubmed: 31292114
pii: S0006-4971(20)70771-8
doi: 10.1182/blood.2019000402
pmc: PMC7042666
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1132-1143

Subventions

Organisme : Austrian Science Fund FWF
ID : I 4154
Pays : Austria
Organisme : Austrian Science Fund FWF
ID : I 4156
Pays : Austria
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 by The American Society of Hematology.

Références

Br J Haematol. 1998 Nov;103(2):488-94
pubmed: 9827924
Bone Marrow Transplant. 2017 Apr;52(4):544-551
pubmed: 27941777
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
Blood. 2008 Jan 1;111(1):328-37
pubmed: 17890451
Blood. 2004 Jul 15;104(2):328-35
pubmed: 15044256
J Clin Oncol. 1994 Dec;12(12):2588-93
pubmed: 7989933
J Clin Oncol. 2008 Mar 1;26(7):1098-105
pubmed: 18309944
Nat Commun. 2018 Feb 15;9(1):697
pubmed: 29449575
Nat Genet. 1997 Sep;17(1):96-9
pubmed: 9288106
Invest Radiol. 2018 Jul;53(7):403-408
pubmed: 29642081
Blood. 2014 Aug 28;124(9):1460-72
pubmed: 24825865
Lancet. 1973 Aug 4;2(7823):232-4
pubmed: 4124423
Cancer Res. 1999 May 15;59(10):2313-7
pubmed: 10344735
Leukemia. 2018 Mar;32(3):774-787
pubmed: 28804127
Cancer Genet Cytogenet. 2003 Nov;147(1):36-43
pubmed: 14580769
Genes Chromosomes Cancer. 2016 Jan;55(1):82-94
pubmed: 26493028
Hematol J. 2000;1(1):42-7
pubmed: 11920168
J Clin Oncol. 2002 Jan 1;20(1):205-13
pubmed: 11773171
JAMA. 2001 Nov 14;286(18):2308-14
pubmed: 11710897
Blood. 2017 Dec 7;130(23):2499-2503
pubmed: 28972014
Leukemia. 2012 May;26(5):972-6
pubmed: 22116553
Mayo Clin Proc. 2005 Dec;80(12):1660-74
pubmed: 16342661
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Blood. 2016 Nov 24;128(21):2489-2496
pubmed: 27574190
Genes Chromosomes Cancer. 2014 Apr;53(4):309-16
pubmed: 24446122
Nat Med. 1997 Oct;3(10):1155-9
pubmed: 9334731
Leukemia. 2007 Oct;21(10):2153-63
pubmed: 17713554
Blood. 2001 Sep 15;98(6):1721-6
pubmed: 11535503
Eur J Haematol. 2015 Mar;94(3):265-9
pubmed: 25130897
Blood. 2008 Jun 15;111(12):5446-56
pubmed: 18216293
Am J Hematol. 1988 Nov;29(3):152-63
pubmed: 3189311
Leuk Lymphoma. 2019 Mar;60(3):649-657
pubmed: 30234404
Leukemia. 2014 Feb;28(2):417-9
pubmed: 24048415
Br J Haematol. 2010 Jun;149(6):907-10
pubmed: 20201944
Blood. 1996 Jun 15;87(12):4990-7
pubmed: 8652811
Blood. 1991 Dec 15;78(12):3269-74
pubmed: 1742486
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2949-51
pubmed: 10077617
Cytometry A. 2018 Nov;93(11):1118-1124
pubmed: 30414304
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Oncotarget. 2017 Nov 1;8(61):104664-104686
pubmed: 29262669
Br J Haematol. 2015 Mar;168(6):916-9
pubmed: 25316212
J Clin Oncol. 2009 Nov 10;27(32):5425-30
pubmed: 19805674
J Clin Oncol. 1997 Jul;15(7):2667-72
pubmed: 9215839
Blood. 2011 Nov 24;118(22):5799-802
pubmed: 21948296
Oncotarget. 2019 Jan 18;10(6):626-628
pubmed: 30774758
N Engl J Med. 2014 Mar 20;370(12):1101-10
pubmed: 24401022
Cancer Genet Cytogenet. 1991 Aug;55(1):1-9
pubmed: 1913594
J Clin Pathol. 2018 Apr;71(4):309-315
pubmed: 28821581
Nouv Rev Fr Hematol. 1982;24(6):343-7
pubmed: 6762526
Br J Haematol. 2016 Apr;173(2):265-73
pubmed: 26917488
Hematology Am Soc Hematol Educ Program. 2015;2015:361-7
pubmed: 26637744
Leukemia. 2007 Feb;21(2):215-21
pubmed: 17170730
Ann Oncol. 2017 Jul 1;28(7):1436-1447
pubmed: 28379322
Cancer. 2013 Jun 15;119(12):2258-67
pubmed: 23512246
Bone Marrow Transplant. 2019 Sep;54(9):1391-1398
pubmed: 30664723
Ann Oncol. 2017 Jul 1;28(7):1554-1559
pubmed: 28379307

Auteurs

Philipp B Staber (PB)

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Marco Herling (M)

Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, and.
Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases, University of Cologne, Cologne, Germany.
Center for Molecular Medicine, University of Cologne, Cologne, Germany.

Mar Bellido (M)

Hematology Department, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Eric D Jacobsen (ED)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Matthew S Davids (MS)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Tapan Mahendra Kadia (TM)

Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX.

Andrei Shustov (A)

Seattle Cancer Care Alliance, University of Washington, Seattle, WA.

Olivier Tournilhac (O)

Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, France.

Emmanuel Bachy (E)

Department of Hematology, Hospices Civils de Lyon, Lyon, France.

Francesco Zaja (F)

S.C. Ematologia Azienda Sanitaria Universitaria Integrata, Trieste, Italy.

Kimmo Porkka (K)

Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.

Gregor Hoermann (G)

Central Institute of Medical and Chemical Laboratory Diagnostics, University Hospital Innsbruck, Innsbruck, Austria.
Department of Laboratory Medicine and.

Ingrid Simonitsch-Klupp (I)

Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria.

Claudia Haferlach (C)

Munich Leukemia Laboratory, Munich, Germany.

Stefan Kubicek (S)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Christian Doppler Laboratory for Chemical Epigenetics and Anti-Infectives, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Marius E Mayerhoefer (ME)

Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.

Georg Hopfinger (G)

Division of Blood and Marrow Transplantation, Department of Medicine I, Medical University of Vienna, Vienna, Austria; and.

Ulrich Jaeger (U)

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Claire Dearden (C)

The Royal Marsden Hospital, NHS Foundation Trust, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH